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This study was initiated to assess the frequency of aspirin resistance among 280 healthy volunteers in Eskisehir, central Anatolia region of Türkiye, and was approved by the Ethics Committee. We also used this prospectively collected population of healthy people to evaluate the correlation of aspirin resistance with clinical and biochemical parameters.
Methods

Study Subjects
The study included 280 healthy Turkish volunteers (179 men, 101 women). All participants were aged 19 years or older and had taken 100 mg of aspirin daily for 7 or more consecutive days before study entry. Demographic information consisting of age, gender, and cardiac risk factors (tobacco use, obesity, hyperlipidemia, family history of coronary artery disease) was collected along with laboratory data that included the blood count, mean platelet volume (MPV), erythrocyte sedimentation rate, and levels for fasting A spirin is a well-established antiplatelet agent with proven benefit in the prevention of atherothrombotic vascular disease. Its effectiveness has been demonstrated in clinical trials and meta-analyses, with a reduction of about 25% in rates of serious arterial thrombotic events in high-risk patients. 1, 2 However, previous studies have estimated that 5% to 45% of the population do not achieve an adequate antiplatelet effect from aspirin and still present with ischemic events despite therapy. [3] [4] [5] [6] [7] The failure of aspirin to prevent an arterial thrombotic event has been termed "aspirin resistance." 8 The data from long-term follow-up clinical studies in patients with cardiovascular, cerebrovascular, and peripheral vascular disease have suggested that aspirin resistance is indeed clinically important. [9] [10] [11] Although the problem of aspirin resistance has been greatly emphasized in the medical literature, it still This study reports the frequency of aspirin resistance and its correlation with clinical and biochemical parameters among 280 healthy Turkish volunteers (179 men, 101 women) who were taking 100 mg of aspirin 7 days or more. Aspirin resistance was detected by optical platelet aggregometry, using adenosine diphosphate and arachidonic acid, and defined as a mean aggregation of 64% or more with 5µM adenosine diphosphate and a mean aggregation of 20% or more with 0.5-mg/mL arachidonic acid. Of the study population, 27.5% (26 women [25. 5 %] and 51 men [28.5 %]) were aspirin resistant. The current findings indicate that aspirin resistance is an important and real laboratory diagnosis given its frequency of 27.5% in the study population. These results of this large trial evaluating the frequency of aspirin resistance in healthy subjects indicate that aspirin resistance should be diagnosed so that individuals with no response can receive alternative or additional antiplatelet therapy.
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Exclusion criteria included ingestion of ticlopidine, dipyridamole, anti-inflammatory drugs, or other drugs affecting platelet function; malignant paraproteinemias, myeloproliferative disorders, or a family or personal history of bleeding disorders; a platelet count of less than 150 × 10 3 /µL or more than 450 × 10 3 /µL, a hemoglobin level of less than 8 g/dL, or a major surgical procedure within 1 week before enrollment.
Platelet Aggregation
Blood samples were drawn into 4.5-mL Vacutainers (Becton Dickinson, Franklin Lakes, NJ) containing 3.8% trisodium citrate in a 9:1 blood anticoagulation ratio by direct vein puncture with 19-gauge needles. The last dose of aspirin was administered within 1 to 24 hours before platelet analysis.
Platelet aggregation studies were performed in whole blood Lumi-Aggregometer (Model 560-Ca, Chrono-Log Corporation, State College, Pa) using the optical method according to manufacturer's instructions. Blood samples were kept at room temperature and processed within 1 hour of collection. The whole-blood specimen was centrifuged for 10 minutes at 200g to obtain platelet rich plasma (PRP). The remaining specimen was recentrifuged at 200g for 15 minutes to obtain platelet poor plasma. The platelet poor plasma was used to adjust the platelet count of the PRP to 300 × 10 3 /µL, and 450 µL of this PRP was transferred into cuvettes (P/N 312, Chrono-Log Corp, Havertown, Pa), each containing a disposable siliconized bar. After agonist addition, platelet aggregation was measured during a 6minute period and expressed as a percentage of the maximal amplitude in PRP. The agonists used and their final concentrations were 5µM of adenosine diphosphate (ADP; Chrono Par 384, Chrono-Log Corp) and 0.5-mg/mL arachidonic acid (AA, Chrono Par 390 Chrono-Log Corp).
Aspirin resistance was defined as a mean aggregation of 64% or more with 5µM of ADP and a mean aggregation of 20% or more with 0.5-mg/mL AA. Laboratory normal reference ranges were established by screening 27 healthy men and women. The definition of aspirin resistance was set as ADPinduced platelet aggregation within the laboratory normal range (>64%). Aspirin usually completely inhibits AA-induced platelet aggregation; therefore, aggregation exceeding 20% was set as the cutoff defining aspirin resistance.
Hematologic Assays
Samples for blood counts were drawn into Becton Dickinson anticoagulated tubes and complete counts were made by using an automated blood counting device (Beckman Coulter Gen-S SM, Fullerton, Calif). Measurement of the erythrocyte sedimentation rate was performed on a Vacuette Automated ESR System (Greiner Bio-One GmbH, Frickenhausen, Germany).
Biochemical Assays
Serum levels of fasting plasma glucose, glycated hemoglobin (HbA 1C ), and a lipid profile, including levels of total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride, were measured by spectrophotometric method on Roche Hitachi 911 Chemistry Analyzer (Roche Diagnostics, Indianapolis, Ind).
Statistical Analysis
Statistical tests were performed using SPSS 13.0 software (SPSS Inc, Chicago, Ill) for Windows (Microsoft Inc, Bellingham, Wash), and differences with a value of P < .05 were considered significant. Categoric variables were compared using χ 2 tests. For continuous variables, the Mann-Whitney U test (if not normally distributed) and independent samples t test (if normally distributed) were used to compare the aspirin-resistant and aspirin-sensitive groups. The Shapiro-Wilk test was performed for testing normality. Results were expressed as mean (SD).
Results
Overall, 77 people (27.5%) were aspirin resistant. Age (P < .001), erythrocyte sedimentation rate (P < .001), and HbA 1C levels (P < .01) were significantly increased in aspirin-resistant individuals compared with aspirin-sensitive individuals. There were significantly more current smokers in the aspirin-sensitive group (P < .05). No significant differences in terms of other cardiac risk factors (obesity, hyperlipidemia and family history of coronary heart disease) and laboratory data (hemoglobin, platelet number, MPV, fasting glucose, and lipids) were noticed between aspirin-resistant and aspirin-sensitive groups.
Baseline characteristics of women are summarized in Table 1 . Among women, 26 (25.5%) were aspirin resistant. Aspirin-resistant women were older (P < .05) and had lower platelet counts (P < .05) and higher MPV levels (P < .05) than aspirin-sensitive women. Other demographic features (tobacco use, obesity, hyperlipidemia, and family history of coronary disease) and laboratory findings (erythrocyte sedimentation rate, and levels of hemoglobin, fasting glucose, and lipids) showed no significant difference between the aspirin-resistant and aspirin-sensitive women.
Baseline characteristics of men are summarized in Table 2 . Among men, 51 (28.5 %) were aspirin resistant. Aspirin-resistant men trended to be older (P < .001) and to have higher total cholesterol levels (P < .05), erythrocyte sedimentation rate (P < .01), platelet counts (P < .05), and HbA 1C levels (P < .01). Aspirin-resistant and aspirin-sensitive men had similar rates of other cardiac risk factors (tobacco use, obesity, and family history of coronary disease) and laboratory data (MPV and levels of hemoglobin, fasting glucose, HDL, and triglyceride).
Discussion
Among 280 healthy Turkish volunteers, our study showed that 27.5% are aspirin resistant. This is the largest trial to date that evaluated the frequency of aspirin resistance in healthy subjects.
Aspirin resistance has been shown to affect patients of all types. Three key studies that have been published on this issue showed that aspirin resistance is indeed clinically important in select populations. Grotemeyer et al, 9 in a cohort of 180 patients with stroke, found that nearly 30% of patients were aspirin nonresponders and were more likely to experience vascular death, myocardial infarction, or cerebrovascular accident compared with aspirin responders (40% vs 4.4%, P ≤ .0001). The study by Mueller et al 10 showed an association between failed inhibition of platelet reactivity by aspirin and the risk of reocclusion after peripheral vascular angioplasty in patients with claudication.
A 2002 study by Eikelboom et al 11 found that patients in the highest quartile of urinary thromboxane B 2 excretion had a relative risk of 3.5 (95% confidence interval, 1.7-7.4) for cardiovascular death compared with those in the lowest quartile.
Laboratory testing has shown that healthy controls without vascular disease have also evidence of aspirin resistance: • In a study by Buchanan et al 12 among 10 healthy volunteers whose bleeding time was not prolonged (aspirin nonresponders), platelet 12-hydroxyeicosatetraenoic acid (12-HETE) synthesis and platelet adhesion were unchanged or increased (P < .001), despite platelet thromboxane A 2 and platelet aggregation being inhibited. • In a recent trial by Fontana et al, 13 true aspirin resistance was reported to be rare among healthy subjects, but aspirin pseudoresistance, defined in terms of PFA-100 (Dade Behring, Inc. Deerfield, Ill) closure time and serum thromboxane B 2 values, was more frequent. Another study similarly found that a full resistance to aspirin was indicated to be unlikely in healthy subjects where PFA-100, which is not a specific test to measure response to this drug, was applied. 14 The current findings indicate that aspirin resistance is an important and real laboratory diagnosis given its high frequency of 27.5% in our study population. This study also extends the previous findings in several important respects. It is a prospective trial that investigates the response of aspirin among the largest number, to date, of healthy participants. The study population consisted of healthy subjects, all lacking risk factors that may influence the effect of aspirin. Moreover, we used optical platelet aggregation, the current gold standard of platelet aggregation, to measure aspirin resistance. Aspirin usage of all participants was also confirmed by measuring salicylate levels.
Aspirin-resistant women were significantly older and had higher MPV values. Increased age has been reported to be associated with increased prevalence of aspirin resistance. 9 It is also possible that increased production of platelets by the bone marrow, introducing into the bloodstream newly formed platelets unexposed to once-daily aspirin dosing, could explain aspirin resistance. 15 In agreement with previous reports, the present data suggest that advanced age and increased platelet turnover are likely to account for the lack of women's response to aspirin.
Aspirin response in men was significantly associated with age, total cholesterol level, erythrocyte sedimentation rate, platelet count, and HbA 1C level. Previous studies confirm that laboratory aspirin resistance predicts cardiovascular risk and that functional aggregometry identifies at-risk individuals. 15 The risk of coronary heart disease increases markedly with age and high levels of serum cholesterol. 16 Today, growing evidence indicates that platelets act as prominent players in the inflammatory component of the coronary heart disease process. 17 The erythrocyte sedimentation rate also gives substantial information in addition to that given by platelets on the risk of coronary heart disease events. 18 In their elegant 2001 study, Khaw et al 19 showed that the HbA 1C level, the 3-month indicator of average blood glucose concentration, was positively associated with the risk of future coronary heart disease, independent of other common cardiovascular risk factors.
Our findings in this current study appear clinically relevant because they nicely point out the association between aspirin resistance and cardiovascular risk factors and inflammatory biomarkers. The presence of this association in men, who have a greater risk of myocardial infarction than women, is also important. Aspirin resistance seems to be a marker of absolute cardiovascular risk in terms of its significant relation with known cardiovascular risk factors and inflammatory markers of atherosclerosis.
Conclusion
Our results demonstrate that aspirin resistance is clinically important. Considering its high frequency in our study population and the dependence on aspirin for its antiplatelet action to decrease adverse events, aspirin resistance should be diagnosed so that individuals with aspirin resistance can be given alternative or additional antiplatelet therapy. In addition to its clinical significance, aspirin resistance probably gives substantial information to that given by known factors on the risk coronary heart disease in apparently healthy subjects.
